Home » Stocks » Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. (ALNA)

Stock Price: $1.51 USD -0.04 (-2.58%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Pre-market: $1.50 -0.01 (-0.66%) Oct 20, 5:15 AM

Stock Price Chart

Key Info

Market Cap 57.56M
Revenue (ttm) n/a
Net Income (ttm) -39.21M
Shares Out 38.12M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $1.51
Previous Close $1.55
Change ($) -0.04
Change (%) -2.58%
Day's Open 1.56
Day's Range 1.50 - 1.58
Day's Volume 386,394
52-Week Range 0.53 - 6.30

More Stats

Market Cap 57.56M
Enterprise Value 39.39M
Earnings Date (est) Dec 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.12M
Float 29.95M
EPS (basic) -1.61
EPS (diluted) -1.59
FCF / Share -1.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.08M
Short Ratio 0.51
Short % of Float 3.59%
Beta 2.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.22
Revenue n/a
Operating Income -38.71M
Net Income -39.21M
Free Cash Flow -36.30M
Net Cash 18.17M
Net Cash / Share 0.48
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -57.61%
ROE -139.91%
ROIC -993.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(418.54% upside)
Current: $1.51
Target: 7.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-47.53-35.59-20.95-24.19-13.91
Net Income-47.34-35.65-21.65-24.51-14.25
Shares Outstanding22.1820.744.521.341.26
Earnings Per Share-2.13-1.72-4.80-18.35-11.35
Operating Cash Flow-43.63-31.84-21.07-23.39-13.18
Capital Expenditures-0.12-0.32-0.06-0.100.01
Free Cash Flow-43.75-32.16-21.12-23.50-13.17
Cash & Equivalents30.0161.6494.4948.7669.01
Total Debt10.499.989.399.596.19
Net Cash / Debt19.5251.6685.1139.1762.83
Book Value17.2049.4682.87-59.28-34.97
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allena Pharmaceuticals, Inc.
Country United States
Employees 29
CEO Louis Brenner

Stock Information

Ticker Symbol ALNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALNA
IPO Date November 2, 2017


Allena Pharmaceuticals, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.